New research suggests that the investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies in treating lung cancer. The drug also provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
Mutations in the growth factor gene EGFR are present in about 10 to 15 percent ...
New research suggests that the investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies in treating lung cancer. The drug also provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
Mutations in the growth factor gene EGFR are present in about 10 to 15 percent ...